Briefing
Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: The randomized AGITG DYNAMIC-Rectal study.
In the ctDNA-guided arm, 42/150 (28%) with successful testing were ctDNA-positive. Adjuvant chemotherapy was used in 46% vs 77% (P<0.001). 3-year RFS was 76% vs 82% (difference 6%, 95% CI -6% to 17%). The abstract states the sample size precludes conclusions about non-inferiority. Recurrence in untreated ctDNA-negative patients was often lung-only (12/15, 80%).
- n: 230 eligible (155 ctDNA-guided, 75 standard); recruitment stopped early because of COVID-19 and uptake of total neoadjuvant therapy
- Assay: tumor-informed (same program as DYNAMIC; commercial name not re-stated in the extracted results)